UK Markets closed
NIKKEI 225
27,782.93 -100.85 (-0.36%) HANG SENG
20,309.13 +116.73 (+0.58%) CRUDE OIL
74.29 +1.32 (+1.81%) GOLD FUTURES
1,998.30 +13.80 (+0.70%) DOW
32,816.27 +98.67 (+0.30%) BTC-GBP
22,516.81 -344.08 (-1.51%)
Beam Therapeutics Inc. (BEAM)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:00PM EDT. Market open.
| Previous close | 31.02 |
| Open | 31.31 |
| Bid | 30.36 x 800 |
| Ask | 30.43 x 1800 |
| Day's range | 29.95 - 31.55 |
| 52-week range | 27.77 - 73.27 |
| Volume | |
| Avg. volume | 923,151 |
| Market cap | 2.137B |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Industry Analysts Just Upgraded Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts By 17%
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will have a reason to smile today, with the analysts making...
- Motley Fool
3 Game-Changing Stocks to Buy in March
Three Motley Fool contributors were asked to select stocks to buy in March that truly are game changers. Here's why they picked Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), and Vertex Pharmaceuticals (NASDAQ: VRTX). Keith Speights (Beam Therapeutics): Base editing is an approach to editing genes invented in 2016 by a team led by David Liu.
- Zacks
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2023 Yahoo. All rights reserved.
